Get all your news in one place.
100’s of premium titles.
One app.
Start reading
The Independent UK
The Independent UK
World
The Associated Press

Johnson & Johnson ordered to pay women over talcum powder cancer cases

A Los Angeles jury has awarded $40 million to two women who claimed that talcum powder manufactured by Johnson & Johnson caused their ovarian cancer.

The healthcare giant immediately announced its intention to appeal the liability verdict and compensatory damages.

This ruling represents the latest development in a protracted legal battle over allegations that talc in Johnson's Baby Powder and Shower to Shower body powder is connected to ovarian cancer and mesothelioma, a cancer affecting the lungs and other organs. Johnson & Johnson stopped selling powder made with talc worldwide in 2023.

Last October, another California jury ordered J&J to pay $966 million to the family of a woman who died of mesothelioma, claiming her cancer developed due to asbestos contamination in the baby powder she used.

Johnson & Johnson replaced the talc in its baby powder sold in most of North America with cornstarch in 2020 after sales declined. (AP Photo/Richard Drew, file)

In the latest case, the jury awarded $18 million to Monica Kent and $22 million to Deborah Schultz and her husband. “The only thing they did was be loyal to Johnson & Johnson as a customer for only 50 years,’’ said their attorney, Daniel Robinson of the Robinson Calcagnie law firm in Newport Beach, California. “That loyalty was a one-way street.’’

Erik Haas, J&J's worldwide vice president of litigation, said in a statement that the company had won “16 of the 17 ovarian cancer cases it previously tried” and expected to do so again upon appealing Friday's verdict.

Haas called the jury's findings "irreconcilable with the decades of independent scientific evaluations confirming that talc is safe, does not contain asbestos, and does not cause cancer.''

Johnson & Johnson replaced the talc in its baby powder sold in most of North America with cornstarch in 2020 after sales declined.

In April, a U.S. bankruptcy court judge denied J&J's plan to pay $9 billion to settle ovarian cancer and other gynecological cancer litiation claims based on talc-related products.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.